We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Are Medical Stocks Lagging ADC Therapeutics (ADCT) This Year?
Read MoreHide Full Article
For those looking to find strong Medical stocks, it is prudent to search for companies in the group that are outperforming their peers. Has ADC Therapeutics SA (ADCT - Free Report) been one of those stocks this year? By taking a look at the stock's year-to-date performance in comparison to its Medical peers, we might be able to answer that question.
ADC Therapeutics SA is one of 889 individual stocks in the Medical sector. Collectively, these companies sit at #6 in the Zacks Sector Rank. The Zacks Sector Rank includes 16 different groups and is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors.
The Zacks Rank is a successful stock-picking model that emphasizes earnings estimates and estimate revisions. The system highlights a number of different stocks that could be poised to outperform the broader market over the next one to three months. ADC Therapeutics SA is currently sporting a Zacks Rank of #2 (Buy).
Within the past quarter, the Zacks Consensus Estimate for ADCT's full-year earnings has moved 34.3% higher. This signals that analyst sentiment is improving and the stock's earnings outlook is more positive.
Based on the latest available data, ADCT has gained about 7.1% so far this year. Meanwhile, stocks in the Medical group have lost about 7.2% on average. As we can see, ADC Therapeutics SA is performing better than its sector in the calendar year.
Bioventus (BVS - Free Report) is another Medical stock that has outperformed the sector so far this year. Since the beginning of the year, the stock has returned 32.7%.
For Bioventus, the consensus EPS estimate for the current year has increased 55.1% over the past three months. The stock currently has a Zacks Rank #2 (Buy).
Looking more specifically, ADC Therapeutics SA belongs to the Medical - Biomedical and Genetics industry, which includes 433 individual stocks and currently sits at #146 in the Zacks Industry Rank. This group has lost an average of 1.2% so far this year, so ADCT is performing better in this area.
On the other hand, Bioventus belongs to the Medical - Drugs industry. This 133-stock industry is currently ranked #94. The industry has moved -1.1% year to date.
Investors interested in the Medical sector may want to keep a close eye on ADC Therapeutics SA and Bioventus as they attempt to continue their solid performance.
Zacks' 7 Best Strong Buy Stocks (New Research Report)
Valued at $99, click below to receive our just-released report
predicting the 7 stocks that will soar highest in the coming month.
View the Zacks #1 Rank List
Image: Bigstock
Are Medical Stocks Lagging ADC Therapeutics (ADCT) This Year?
For those looking to find strong Medical stocks, it is prudent to search for companies in the group that are outperforming their peers. Has ADC Therapeutics SA (ADCT - Free Report) been one of those stocks this year? By taking a look at the stock's year-to-date performance in comparison to its Medical peers, we might be able to answer that question.
ADC Therapeutics SA is one of 889 individual stocks in the Medical sector. Collectively, these companies sit at #6 in the Zacks Sector Rank. The Zacks Sector Rank includes 16 different groups and is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors.
The Zacks Rank is a successful stock-picking model that emphasizes earnings estimates and estimate revisions. The system highlights a number of different stocks that could be poised to outperform the broader market over the next one to three months. ADC Therapeutics SA is currently sporting a Zacks Rank of #2 (Buy).
Within the past quarter, the Zacks Consensus Estimate for ADCT's full-year earnings has moved 34.3% higher. This signals that analyst sentiment is improving and the stock's earnings outlook is more positive.
Based on the latest available data, ADCT has gained about 7.1% so far this year. Meanwhile, stocks in the Medical group have lost about 7.2% on average. As we can see, ADC Therapeutics SA is performing better than its sector in the calendar year.
Bioventus (BVS - Free Report) is another Medical stock that has outperformed the sector so far this year. Since the beginning of the year, the stock has returned 32.7%.
For Bioventus, the consensus EPS estimate for the current year has increased 55.1% over the past three months. The stock currently has a Zacks Rank #2 (Buy).
Looking more specifically, ADC Therapeutics SA belongs to the Medical - Biomedical and Genetics industry, which includes 433 individual stocks and currently sits at #146 in the Zacks Industry Rank. This group has lost an average of 1.2% so far this year, so ADCT is performing better in this area.
On the other hand, Bioventus belongs to the Medical - Drugs industry. This 133-stock industry is currently ranked #94. The industry has moved -1.1% year to date.
Investors interested in the Medical sector may want to keep a close eye on ADC Therapeutics SA and Bioventus as they attempt to continue their solid performance.